Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models.
暂无分享,去创建一个
Claudio N. Cavasotto | Sharangdhar S. Phatak | Claudio N Cavasotto | Santiago Vilar | Giulio Ferino | Stefano Costanzi | Sharangdhar S Phatak | S. Vilar | C. Cavasotto | S. Costanzi | G. Ferino | Barkin Berk | B. Berk | Giulio Ferino
[1] Stefano Costanzi,et al. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. , 2008, Journal of the American Chemical Society.
[2] Nagarajan Vaidehi,et al. Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation. , 2008, Biophysical journal.
[3] Claudio N. Cavasotto and Narender Singh. Docking and High Throughput Docking: Successes and the Challenge of Protein Flexibility , 2008 .
[4] Michel Bouvier,et al. Insights into signaling from the beta2-adrenergic receptor structure. , 2008, Nature chemical biology.
[5] Gerhard Hummer,et al. Atomistic insights into rhodopsin activation from a dynamic model. , 2008, Journal of the American Chemical Society.
[6] Peter L. Freddolino,et al. Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] Holger Gohlke,et al. Target flexibility: an emerging consideration in drug discovery and design. , 2008, Journal of medicinal chemistry.
[8] Marta Filizola,et al. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[9] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[10] Peter Kolb,et al. Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.
[11] M. Gershengorn,et al. Seven Transmembrane-spanning Receptors for Free Fatty Acids as Therapeutic Targets for Diabetes Mellitus: Pharmacological, Phylogenetic, and Drug Discovery Aspects* , 2008, Journal of Biological Chemistry.
[12] Claudio N. Cavasotto,et al. Conformational Sampling of Protein Flexibility in Generalized Coordinates: Application to Ligand Docking , 2005 .
[13] Stefano Costanzi,et al. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. , 2008, Journal of medicinal chemistry.
[14] R. Friesner,et al. Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.
[15] Ruben Abagyan,et al. Identifying conformational changes of the β2 adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators , 2009, J. Comput. Aided Mol. Des..
[16] Stefano Costanzi,et al. On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.
[17] G. Müller. Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach. , 2000, Current medicinal chemistry.
[18] M. Gershengorn,et al. Two Arginine-Glutamate Ionic Locks Near the Extracellular Surface of FFAR1 Gate Receptor Activation* , 2009, Journal of Biological Chemistry.
[19] R. Stevens,et al. GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.
[20] Stefano Costanzi,et al. Identification of Residues Important for Agonist Recognition and Activation in GPR40* , 2007, Journal of Biological Chemistry.
[21] B. Shoichet,et al. Soft docking and multiple receptor conformations in virtual screening. , 2004, Journal of medicinal chemistry.
[22] Somesh D. Sharma,et al. Managing protein flexibility in docking and its applications. , 2009, Drug discovery today.
[23] Santiago Vilar,et al. Ligand and structure‐based models for the prediction of ligand‐receptor affinities and virtual screenings: Development and application to the β2‐adrenergic receptor , 2009, J. Comput. Chem..
[24] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[25] J. Ballesteros,et al. The Forgotten Serine , 2000, The Journal of Biological Chemistry.
[26] Claudio N. Cavasotto,et al. 2,3‐Dihydro‐1‐Benzofuran Derivatives as a Series of Potent Selective Cannabinoid Receptor 2 Agonists: Design, Synthesis, and Binding Mode Prediction through Ligand‐Steered Modeling , 2009, ChemMedChem.
[27] Claudio N. Cavasotto,et al. Ligand-Steered Modeling and Docking: A Benchmarking Study in Class A G-Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..
[28] Claudio N. Cavasotto,et al. Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.
[29] Claudio N. Cavasotto,et al. Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.
[30] K. Jacobson,et al. Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. , 2005, Journal of medicinal chemistry.
[31] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[32] B. Raaka,et al. Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. , 2007, Journal of medicinal chemistry.
[33] D. Rognan,et al. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.
[34] Dov Barak,et al. Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.
[35] Claudio N. Cavasotto,et al. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. , 2008, Journal of medicinal chemistry.
[36] Sharangdhar S. Phatak,et al. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction. , 2009, Journal of medicinal chemistry.
[37] Raymond C Stevens,et al. Discovery of new GPCR biology: one receptor structure at a time. , 2009, Structure.
[38] Olivier Sperandio,et al. How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis , 2010, European Biophysics Journal.
[39] C. Strader,et al. Structure and function of G protein-coupled receptors. , 1994, Annual review of biochemistry.
[40] I. Tikhonova,et al. Unraveling the structure and function of G protein-coupled receptors through NMR spectroscopy. , 2009, Current pharmaceutical design.
[41] Nagarajan Vaidehi,et al. Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor. , 2010, Journal of the American Chemical Society.
[42] Stefano Costanzi,et al. Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. , 2009, Current pharmaceutical design.
[43] B. Raaka,et al. Understanding the structural and functional differences between mouse thyrotropin‐releasing hormone receptors 1 and 2 , 2008, Proteins.
[44] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..